Exeltis Usa Inc Drug Patent Portfolio
Exeltis Usa Inc owns 3 orange book drugs protected by 16 US patents Given below is the list of Exeltis Usa Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10179140 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same | 28 Jun, 2031 | Active |
| US10603281 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same | 28 Jun, 2031 | Active |
| US10849857 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same | 28 Jun, 2031 | Active |
| US10987364 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US11123299 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US11291632 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US11291633 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US11351122 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US11413249 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US11439598 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US11478487 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US11504334 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US11951213 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US12090231 | Synthetic progestogens and pharmaceutical compositions comprising the same | 28 Jun, 2031 | Active |
| US9603860 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same | 28 Jun, 2031 | Active |
| US5629021 | Micellar nanoparticles | 31 Jan, 2015 | Expired |
Latest Legal Activities on Exeltis Usa Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Exeltis Usa Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jun, 2024 | US10849857 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Apr, 2024 | US11951213 |
|
Email Notification
Critical
| 09 Apr, 2024 | US11951213 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951213 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951213 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951213 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Apr, 2024 | US11951213 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11951213 |
|
Issue Notification Mailed
Critical
| 20 Mar, 2024 | US11951213 |
| Dispatch to FDC | 01 Mar, 2024 | US11951213 |
|
Application Is Considered Ready for Issue
Critical
| 01 Mar, 2024 | US11951213 |
|
Issue Fee Payment Verified
Critical
| 27 Feb, 2024 | US11951213 |
|
Issue Fee Payment Received
Critical
| 27 Feb, 2024 | US11951213 |
| Mail Post Card | 21 Feb, 2024 | US11951213 |
|
Mail Notice of Allowance
Critical
| 14 Feb, 2024 | US11951213 |
Exeltis Usa Inc Drug Patents' Oppositions Filed in EPO
Exeltis Usa Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 12, 2022, by Adalvo Ltd.. This opposition was filed on patent number EP19209672A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19209672A | Oct, 2022 | Luigi, Rumi | Granted and Under Opposition |
| EP19209672A | Oct, 2022 | Adalvo Ltd. | Granted and Under Opposition |
Exeltis Usa Inc's Family Patents
Exeltis Usa Inc drugs have patent protection in a total of 28 countries. It's US patent count contributes only to 26.0% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Exeltis Usa Inc Drug List
Given below is the complete list of Exeltis Usa Inc's drugs and the patents protecting them.
1. Drospirenone
Drospirenone is protected by 15 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10179140 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
28 Jun, 2031
(6 years from now)
| Active |
| US10603281 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
28 Jun, 2031
(6 years from now)
| Active |
| US10849857 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
28 Jun, 2031
(6 years from now)
| Active |
| US10987364 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11123299 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11291632 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11291633 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11351122 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11413249 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11439598 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11478487 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11504334 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11951213 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US12090231 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US9603860 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
28 Jun, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Drospirenone's drug page
2. Estrasorb
Estrasorb is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5629021 | Micellar nanoparticles |
31 Jan, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Estrasorb's drug page
3. Slynd
Slynd is protected by 15 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10179140 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
28 Jun, 2031
(6 years from now)
| Active |
| US10603281 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
28 Jun, 2031
(6 years from now)
| Active |
| US10849857 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
28 Jun, 2031
(6 years from now)
| Active |
| US10987364 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11123299 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11291632 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11291633 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11351122 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11413249 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11439598 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11478487 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11504334 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US11951213 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US12090231 | Synthetic progestogens and pharmaceutical compositions comprising the same |
28 Jun, 2031
(6 years from now)
| Active |
| US9603860 | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
28 Jun, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Slynd's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List